Instrument Inactif

Communiqués CanaQuest Medical Corp Other OTC

Actions

CANAQUEST Announces Award of European Cannabinoid Patent	20/09/23	AQ
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health and Pharma for their 8th Annual Healthcare and Pharmaceutical Program	27/07/23	AQ
CanaQuest Medical : Interim Consolidated Consolidated Financial Statements (unaudited) - June 30, 2022	08/08/22	PU
CanaQuest Medical : Attorney Letter	18/07/22	PU
CanaQuest Medical : Financial Statements (unaudited) - March 31, 2022	14/06/22	PU
CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL	17/09/20	GL
UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE	14/07/20	GL
CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE	14/07/20	GL
Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®	06/02/20	GL
CanaQuest Medical Corp. Joins Stock Day Podcast to Discuss Global Expansion Plans	25/11/19	NE
CANAQUEST MEDICAL CORP is the Winner of the Go Global Awards "Business of the Year – Category of Life Science” presented by the International Trade Council	29/10/19	GL
CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT	17/09/19	GL

Aucun résultat pour cette recherche